Tuberculosis
RSSArticles
-
TB Screening Dismayingly Low in Those at Risk
Screening for latent tuberculosis (TB) infection in persons at risk is woefully lax in our country — and yet, reactivation TB is such an eminently preventable disease.
-
Shortening the Duration of Tuberculosis Treatment
In patients with rifampin-susceptible tuberculosis, a planned eight-week regimen of bedaquiline plus linezolid together with isoniazid, ethambutol, and pyrazinamide, combined with a careful follow-on strategy, was non-inferior to a standard six-month regimen.
-
An Effective Oral Regimen for Rifampin-Resistant Tuberculosis
A multicenter, randomized, controlled, noninferiority clinical trial found a 24-week, all-oral regimen (bedaquiline, pretomanid, linezolid, and moxifloxacin) to be safe and effective for patients aged 15 years and older with rifampin-resistant tuberculosis.
-
Multi-State Tuberculosis Outbreak Due to Transmission from an Infected Bone Graft Product
An 80-year-old man with undiagnosed tuberculosis (TB) became a bone tissue donor after his death from a cardiac arrest. Bone graft product was given to 113 recipients in 20 states, of whom three died of TB. All living recipients were started on treatment for TB at a median of 69 days after bone product implementation.
-
Infectious Disease Alert Updates
Screening for Chagas in HIV; It’s Not All About the Cough; Linezolid and Cycloserine in CSF Adequate
-
Pediatric Tuberculosis
Mycobacterium tuberculosis (MTB) is a significant challenge to children's health. Barriers exist at multiple levels of the care system for MTB. Early recognition and involvement of MTB specialists is critical to facilitate the best outcome for pediatric patients. The authors provide a thorough review of the current standards for care of these challenging patients.
-
Rifampin vs. Isoniazid for Latent Tuberculosis
A health system cost comparison showed that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.
-
2020 Updated LTBI Treatment Guidelines
A committee recommended three rifamycin-based regimens and two alternate six- or nine-month isoniazid monotherapy regimens for latent tuberculosis infection treatment. They gave priority to shorter-course regimens with similar efficacy, higher rates of completion, and favorable tolerability compared with the former standard nine-month regimen of isoniazid.
-
Special Coverage: 9th Conference on Retroviruses - TB, pneumonia deaths down, but heart attacks up
-
Community-based efforts chalk up successes